PACMA 31

• Description :

  PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues[1]. PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

• CAS Number :

  [1401089-31-3]

• UNSPSC :

  12352005

• Hazard Statement :

  H301

• Target :

  PDI

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pacma-31.html

• Purity :

  99.32

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  COC1=CC=C(N(C(C2=CC=CS2)C(NCC(OCC)=O)=O)C(C#C)=O)C(OC)=C1

• Molecular Formula :

  C21H22N2O6S

• Molecular Weight :

  430.47

• Precautions :

  H301

• References & Citations :

  [1]Xu S, et al. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci U S A. 2012;109 (40) :16348-16353.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported